Technical Analysis for ZFGN - Zafgen, Inc.

Grade Last Price % Change Price Change
grade F 0.7358 -6.15% -0.05
ZFGN closed down 6.15 percent on Friday, October 18, 2019, on 31 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical ZFGN trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish -6.15%
Upper Bollinger Band Walk Strength -6.15%
Inside Day Range Contraction -6.15%
Above Upper BB Strength -6.15%
Up 3 Days in a Row Strength -6.15%
Up 4 Days in a Row Strength -6.15%
Up 5 Days in a Row Strength -6.15%
Upper Bollinger Band Touch Strength -6.15%

Older signals for ZFGN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity. Beloranib, the Company’s product candidate, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms, including hyperphagia and obesity. Craniopharyngioma is a rare form of benign brain tumor that occurs near the optic nerve, pituitary gland and hypothalamus. Approximately 30% to 50% of cases of craniopharyngioma are diagnosed in childhood and adolescence.
Medicine Biopharmaceutical Organ Systems Obesity Neuroendocrinology Prader Willi Syndrome
Is ZFGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.7
52 Week Low 0.64
Average Volume 536,189
200-Day Moving Average 2.2953
50-Day Moving Average 0.7693
20-Day Moving Average 0.725
10-Day Moving Average 0.7322
Average True Range 0.0432
ADX 15.72
+DI 18.7893
-DI 17.7473
Chandelier Exit (Long, 3 ATRs ) 0.6654
Chandelier Exit (Short, 3 ATRs ) 0.8145
Upper Bollinger Band 0.7673
Lower Bollinger Band 0.6827
Percent B (%b) 0.63
BandWidth 11.668966
MACD Line -0.0072
MACD Signal Line -0.0177
MACD Histogram 0.0105
Fundamentals Value
Market Cap 20.22 Million
Num Shares 27.5 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -0.39
Price-to-Sales 0.00
Price-to-Book 0.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.81
Resistance 3 (R3) 0.82 0.80 0.80
Resistance 2 (R2) 0.80 0.78 0.80 0.79
Resistance 1 (R1) 0.77 0.77 0.76 0.76 0.79
Pivot Point 0.75 0.75 0.75 0.75 0.75
Support 1 (S1) 0.72 0.73 0.71 0.71 0.68
Support 2 (S2) 0.70 0.72 0.70 0.68
Support 3 (S3) 0.67 0.70 0.67
Support 4 (S4) 0.66